secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001628280-23-003635
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Regains Full Rights to ARO-PNPLA3 After Janssen Terminates Collaboration
--------------------------------------------------------------------------------

- Janssen terminated the Research Collaboration and Option Agreement with Arrowhead effective April 7, 2023.
- Arrowhead regains all rights and licenses to ARO-PNPLA3 (formerly JNJ-75220795), a NASH candidate.
- Phase 1 data showed up to 40% mean reduction in liver fat in PNPLA3 I148M homozygotes after a single dose.
- No serious adverse events reported; safety profile encouraging with mostly mild AEs.
- Arrowhead plans to design a Phase 2 study and assess options for communicating full Phase 1 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828023003635/0001628280-23-003635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828023003635/arwr-20230210.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-003635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer